PREA Update Hung Up Over Concerns About Implementation Criteria

As Senate and House committee leaders work out differences between their respective FDA user fee bills, one amendment intended to increase development of childhood cancer drugs has yet to be included in the bill in either chamber, despite strong bipartisan support. Uncertainty about how the bill -- the Research to Accelerate Cures and Equity (RACE) for Children Act -- would be implemented, is one source of concern for industry and other stakeholders, a cancer research advocate tells Inside Health Policy...